HIV Vaccines
Although there isn't currently an AIDS antibody, efforts to develop an immunization against HIV, the infection that causes AIDS, have been ongoing for a very long time. A HIV antibody may be effective in either of two ways. A "preventive" immunization would prevent HIV contamination from occurring entirely, whereas a "remedial" antibody would not prevent sickness but would treat or delay illness in people who become contaminated and may also reduce the risk of them spreading the infection to others. Even though a protective antibody would be ideal, beneficial vaccines would also be incredibly beneficial. The main goal of all HIV vaccinations is to strengthen the immune system of humans so they can fight HIV.
- BNT162b2/COMIRNATY Tozinameran (INN)-BioNTech Manufacturing GmbH
- AZD1222 Vaxzervria --AstraZeneca, AB
Related Conference of HIV Vaccines
7th International Conference on Vaccines, Immunology and Clinical Trials
HIV Vaccines Conference Speakers
Recommended Sessions
- HIV Vaccines
- Cancer, Malaria & TB Vaccinesv
- Combination & Conjugate Vaccines
- DNA & Synthetic Vaccines
- Human Vaccines Against Infectious Diseases
- New Trends in Vaccines Development
- Pediatric Vaccines
- RDT in Antibiotic Research
- Side-effects of Vaccines
- Toxoid Vaccines
- Vaccine Production & Development
- Vaccine Safety & Efficacy
- Vaccines
- Vaccines for Pregnant Women
- Vaccines for Unconventional Diseases
- Vaccines Manufacturing Technologies
- Vaccines Research and Clinical Trails
- Zika Virus Vaccines
Related Journals
Are you interested in
- Antiviral Therapies - Virology 2024 (Austria)
- Basic Immunology - Virology 2024 (Austria)
- Challenges in Global Vaccination Programs - Vaccines R&D 2024 (Netherlands)
- Clinical Immunology - Virology 2024 (Austria)
- Clinical Trials: Safety, Efficacy, and Beyond - Vaccines R&D 2024 (Netherlands)
- COVID19 Vaccines - VACCINE CONGRESS 2024 (Spain)
- Cutting-Edge Techniques in Vaccine Manufacturing - Vaccines R&D 2024 (Netherlands)
- Emerging Infectious Diseases and Global Health - VACCINES WORLD 2024 (Canada)
- Emerging Viral Diseases - Virology 2024 (Austria)
- Epidemiology and Public Health - Virology 2024 (Austria)
- Ethical and Societal Aspects of Vaccination - VACCINES WORLD 2024 (Canada)
- Gene Editing for Vaccine Development - Vaccines R&D 2024 (Netherlands)
- Geriatric Vaccines - VACCINE CONGRESS 2024 (Spain)
- Global Vaccine Access - VACCINE CONGRESS 2024 (Spain)
- Immune System and Non-Infectious Diseases - Vaccines R&D 2024 (Netherlands)
- Immunization in Special Populations - VACCINES WORLD 2024 (Canada)
- Immunodiagnostics and Monitoring Immune Responses - VACCINES WORLD 2024 (Canada)
- Immunogenetics and Genomics - Virology 2024 (Austria)
- Immunogenetics and Personalized Vaccinology - VACCINES WORLD 2024 (Canada)
- Immunology and Infectious Diseases: Current Landscape - Vaccines R&D 2024 (Netherlands)
- Immunology of Aging and Vaccination - Vaccines R&D 2024 (Netherlands)
- Immunology of Vaccines - VACCINE CONGRESS 2024 (Spain)
- Immunometabolism - Virology 2024 (Austria)
- Immunopathology and Host-Pathogen Interactions - VACCINES WORLD 2024 (Canada)
- Immunotherapy - Virology 2024 (Austria)
- Immunotherapy: Novel Strategies and Technologies - Vaccines R&D 2024 (Netherlands)
- Infectious Diseases and Immunity - Virology 2024 (Austria)
- Inflammation and Immune Response - Virology 2024 (Austria)
- Innate and Adaptive Immune Responses - VACCINES WORLD 2024 (Canada)
- Innovative Approaches to Vaccine Design - Vaccines R&D 2024 (Netherlands)
- Innovative Immunotherapies - VACCINES WORLD 2024 (Canada)
- Next Generation Vaccines - VACCINE CONGRESS 2024 (Spain)
- Next-Generation Vaccines: Advancements and Challenges - Vaccines R&D 2024 (Netherlands)
- Novel Vaccine Platforms - VACCINE CONGRESS 2024 (Spain)
- One Health Approach - VACCINE CONGRESS 2024 (Spain)
- Paediatric Vaccines - VACCINE CONGRESS 2024 (Spain)
- Precision Medicine and Personalized Vaccines - Vaccines R&D 2024 (Netherlands)
- Public Health and Vaccination Programs - VACCINES WORLD 2024 (Canada)
- Public-Private Partnerships for Vaccine Research - Vaccines R&D 2024 (Netherlands)
- Regulatory Guidelines for Vaccine Approval - Vaccines R&D 2024 (Netherlands)
- The Future of Vaccinology: Trends and Prospects - Vaccines R&D 2024 (Netherlands)
- Vaccination Strategies for Vector-Borne Diseases - VACCINES WORLD 2024 (Canada)
- Vaccine Adjuvants - VACCINE CONGRESS 2024 (Spain)
- Vaccine Clinical Trials - VACCINE CONGRESS 2024 (Spain)
- Vaccine Delivery Systems - VACCINE CONGRESS 2024 (Spain)
- Vaccine Development - Virology 2024 (Austria)
- Vaccine Development and Design - VACCINES WORLD 2024 (Canada)
- Vaccine Development for Emerging Diseases - VACCINE CONGRESS 2024 (Spain)
- Vaccine Economics and Market Access - VACCINES WORLD 2024 (Canada)
- Vaccine Education and Advocacy - VACCINES WORLD 2024 (Canada)
- Vaccine Equity - VACCINE CONGRESS 2024 (Spain)
- Vaccine Financing - VACCINE CONGRESS 2024 (Spain)
- Vaccine Hesitancy - VACCINE CONGRESS 2024 (Spain)
- Vaccine Hesitancy: Causes and Solutions - Vaccines R&D 2024 (Netherlands)
- Vaccine Immunogenicity - VACCINE CONGRESS 2024 (Spain)
- Vaccine Manufacturing - VACCINE CONGRESS 2024 (Spain)
- Vaccine Policy and Regulation - VACCINE CONGRESS 2024 (Spain)
- Vaccine Safety - VACCINE CONGRESS 2024 (Spain)
- Vaccine Safety and Adverse Event Monitoring - VACCINES WORLD 2024 (Canada)
- Vaccine Surveillance - VACCINE CONGRESS 2024 (Spain)
- Vaccines Epidemiology - VACCINE CONGRESS 2024 (Spain)
- Vaccines for Non-Communicable Diseases - VACCINES WORLD 2024 (Canada)
- Vaccines Immunology - VACCINE CONGRESS 2024 (Spain)
- Viral Diagnostics - Virology 2024 (Austria)
- Viral Genomics and Evolution - Virology 2024 (Austria)
- Viral Immunology - Virology 2024 (Austria)
- Viral Pathogenesis - Virology 2024 (Austria)
- Viral Vaccines - Virology 2024 (Austria)